On-Demand Webinar , GLP1 , Oral Peptides , Dr. Andy Lewis , Dr. Stuart Mair

On-Demand: Development of Orally Delivered GLP-1 Therapeutics …From Diabetes to Obesity and Beyond

18 July 2024
Overview

Dr. Andrew Lewis, Chief Scientific Officer, and Dr. Stuart Mair, Chief Medical Officer explore the latest developments in orally delivered GLP-1 agonists and take a look at potential future innovations. 

Our expert speakers examine obesity as a global health issue, discussing its profound impact on healthcare; guide us through the discovery of GLP-1 agonists and the potential for these therapeutics outside diabetes; and explore the challenges and potential solutions for orally-delivered GLP-1 products. 

You'll learn about:

  • Drivers for oral incretin analogues and the CMC and clinical challenges in their development
  • How Quotient Sciences' Translational Pharmaceutics® platform has enabled the accelerated development of both orally delivered peptides and small molecules in the incretin family
  • Future innovation in GLP-1 agonists and oral peptides

Watch our on-demand recording and stay at the forefront of treatment advancements in this quickly evolving category.

Watch
Date
18 July 2024

Meet our speakers:

Our expert speakers will examine obesity as a global health issue, discussing its profound impact on healthcare.

Dr. Andrew Lewis

Chief Scientific Officer

Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...

About Andrew
Dr. Stuart Mair

Global VP, Medical, Early Development

Dr. Stuart (Stu) Mair has over 16 years of experience delivering exploratory clinical studies in the contract research organizatio...

About Stuart

More from our experts

PharmTech.com and Pharmaceutical Technology Europe logos
Articles & Publications, Dr. Andy Lewis

Video Interview: Dr. Andrew Lewis Discusses CMC Challenges for GLP-1 and Oral Peptides with PharmTech Europe

By: Dr. Andrew Lewis Read Now
Upcoming Webinar
Join us for "A Deep Dive Into the CMC, Technology and Financial Aspects of Successful Development of an Orally Delivered GLP-1"